Project development plan

GBC-HpVac is developing the asset GBC-R1, for which it owns an exclusive license, with an overall valorization horizon of approx. 50 months, aiming for a potential exit or co-development with a commercial partner either with a drug candidate ready for clinical trials in humans, or after a future proof-of-concept (PoC) phase IIa clinical trial.

 

After successfully securing financing for the Lead Validation phase in 2018, GBC-HpVac is currently running a funding call for a total of CHF 8 Million, to be invested in two success-based tranches. A first tranche of CHF 3 million to be completed by early 2020 followed by a second of CHF 5 million expected to take place by late 2021.

Aim:

GMP production & stability, drug substance and documentation ready for clinical trial submission(s)

Duration:

12-18 months

Costs:

CHF 5 million

Funding:

open

Aim:

identification of recombinant lead molecule, bioequivalence, mechanism of action

Duration:

approx. 12 month

Costs:

approx. CHF 1 Mio

Funding:

secured

Aim:

optimized molecule ready for GMP production, stability tests and preclinical stage

Duration:

18-24 months (depending on the number of validation cycles required)

Costs:

CHF 3 million

Funding:

ongoing

Opportunities

GBC-HpVac is currently open to industrial and/or financial partners to collaborate on the next phases of its pre-clinical development programme.

 

Financial partners will be able to rely on the GBC's tested, solid expertise, based on over 20 years' experience in business and pharmaceutical development, and on the company's wide network of specialized consultants and CROs.

 

Interested parties are welcome to contact us on : hpvac@gbc-sa.com

Health market

The mode of action of GBC-R1 suggests that it could be deployed against several indications of the atopic march, e.g. atopic dermatitis, allergic asthma and allergic rhinitis, as well as other indications such as IBD or celiac disease.

 

The prevalence of all possible indications is on the rise; 5-year CAGR forecasts range from 2.8% (ulcerative colitis) to 9.7% (allergic rhinitis). The worldwide health costs caused by these indications together may exceed 55 Billion USD in 20231), while the pharmaceutical industry struggles to find affordable and effective alternatives to current standard treatments.

1) GlobalData Plc, 2018.